All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Fabentech secures French approval for Ricimed polyclonal antibody antidote targeting ricin poisoning
Antibody, infectious disease, polyclonal antibody, ricin poisoning, biodefense - Read more

Sanofi's Teizeild (teplizumab) wins EU approval to delay onset of type 1 diabetes following Ph2 success
Antibody, autoimmune, monoclonal antibody, type 1 diabetes, CD3 target, disease modification - Read more

THE GOOD
Business Development & Partnerships

Novartis, SciNeuro Pharmaceuticals partner on Alzheimer's anti-amyloid antibody program, $165M upfront, $1.5B milestones
Licensing deal, neurological, antibody, milestone payments - Read more

AbbVie, RemeGen partner on PD-1/VEGF bispecific RC148, $650M upfront, $4.95B milestones
Licensing deal, oncology, bispecific antibody, milestone payments - Read more

Bio-Sourcing, Zerion Pharma partner on oral HER2 breast cancer antibody, €1.3M ($1.5M) funding
Co-development, oncology, antibody, drug discovery, milestone payments - Read more

TetraScience, Thermo Fisher Scientific collaborate to accelerate scientific data and AI enablement across laboratories
Research collaboration, AI/ML, drug discovery, R&D, manufacturing - Read more

Formosa Pharmaceuticals, Samil Pharmaceuticals license clobetasol propionate ophthalmic suspension with upfront payment and milestones
Licensing deal, ophthalmology, small molecule, commercialization, milestone payments - Read more

Eli Lilly, NVIDIA jointly invest $1B in AI co-innovation lab for drug discovery acceleration
Research collaboration, AI/ML, drug discovery, manufacturing, joint venture - Read more

Nuvation Bio, Eisai license taletrectinib for Europe and additional territories, €50M ($58M) upfront, €195M ($226.7M) total
Licensing deal, oncology, small molecule, milestone payments, commercialization - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Lynk Pharmaceuticals' zemprocitinib (LNK01001) hits Ph3 primary endpoint for JAK1 inhibition in rheumatoid arthritis
Small molecule, autoimmune, JAK inhibitor, rheumatoid arthritis, selective JAK1 inhibition - Read more

Bristol Myers Squibb's Camzyos (mavacamten) hits Ph3 goals for adolescent obstructive hypertrophic cardiomyopathy treatment
Small molecule, cardiovascular, cardiac myosin inhibitor, obstructive hypertrophic cardiomyopathy, adolescent patients - Read more

Oxford Drug Design reports positive preclinical results for novel colorectal cancer therapy targeting KRAS-mutated tumors
Small molecule, cancer, colorectal cancer, KRAS mutations, rapamycin resistance - Read more

THE GOOD
Earnings & Finances

Moderna hits $1.9B 2025 revenue goal while cutting operating expenses faster than expected amid cost reduction drive
mRNA vaccine, infectious disease, cost reduction, financial - Read more

Mesoblast shares rise 5.5% after Ryoncil Q4 revenue jumps 60% to $35.1 million
Cell therapy, rare disease, revenue impact, strategic - Read more

THE GOOD
Fundraises

Trailhead Biosystems raises $40M funding, advancing human cell innovation platform
Cell therapy, platform technology, iPSC, biomedical research - Read more

Oricell Therapeutics raises $70M Series C, accelerating solid tumor CAR-T therapies development
Cancer, CAR-T therapy, cell therapy, oncology, clinical-stage - Read more

bit.bio raises $50M funding, human cell programming technology for drug discovery
Cell therapy, AI/ML platform, drug discovery, platform technology - Read more

FluoSphera raises €1.23M ($1.43M) funding, 3D tissue platform for drug testing
Drug discovery, platform technology, in vitro testing, AI-driven - Read more

Arkin Capital closes $100M Fund III, early-stage biotech investments globally
Venture capital, preclinical, clinical-stage, oncology, immunology, rare disease - Read more

Avenue Biosciences raises $5.7M Seed extension, protein engineering technology platform
Protein engineering, AI/ML platform, platform technology, manufacturing - Read more

Cytotheryx raises $60M Series A, cell therapy for liver disease
Cell therapy, liver disease, preclinical, bioartificial liver, rare disease - Read more

Vibrant Therapeutics raises $61M funding, logic-gated therapeutics for disease microenvironments
Clinical-stage, oncology, platform technology, T-cell engager, AI-driven - Read more

THE GOOD
Investments

AbbVie to acquire West Pharmaceutical Services' Arizona device manufacturing facility for $175M investment
Drug delivery device, immunology, operational, major transaction - Read more

Cellares expands cell therapy factory-in-a-box operations to Europe with new Netherlands manufacturing facility lease
Cell therapy, strategic, operational, manufacturing expansion - Read more

Jubilant Biosys announces new discovery and preclinical facility in India, doubling CRDMO chemistry capacity
Small molecule, operational, capacity expansion, contract research - Read more

THE GOOD
Marketing

Domain Therapeutics rebrands as Kainova Therapeutics, advancing clinical pipeline of GPCR-modulating therapies for immuno-oncology and inflammation
Monoclonal antibody, oncology, strategic, operational - Read more

THE GOOD
Mergers & Acquisitions

insitro to acquire CombinAbleAI to complete full stack AI platform for drug discovery and design
Multi-modal therapeutics, strategic, major transaction, operational - Read more

Eli Lilly reportedly ready with €15B bid to acquire Abivax for ulcerative colitis drug obefazimod
Small molecule, autoimmune, strategic, major transaction - Read more

THE GOOD
Regulatory

FDA lifts partial hold on Daiichi Sankyo, Merck & Co.'s lung cancer ADC trial after safety measures implemented
Antibody-drug conjugate, oncology, regulatory, strategic - Read more

THE GOOD
Strategic Plans

Sanofi CEO maintains long-term vaccine strategy despite US administration's "sensitivity" around childhood vaccination policies
Monoclonal antibody, infectious disease, strategic, regulatory - Read more

Pfizer CEO Bourla outlines obesity strategy following Metsera acquisition, launches Phase III trials for MET-097i
GLP-1 agonist, obesity, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA issues second complete response letter for Atara Biotherapeutics and Pierre Fabre's Ebvallo (tabelecleucel) targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease
Cell therapy, cancer, T-cell immunotherapy, post-transplant lymphoproliferative disease, EBV target - Read more

THE BAD
Earnings & Finances

Apellis shares tumble 14% as Syfovre eye treatment sales decline 4% to $587M in 2025
Complement inhibitor, ophthalmology, financial, revenue impact - Read more

THE BAD
Market Reports

JPM reports early-stage biotech funding fell to $8.7B in 2025 as investors favor derisked assets
Financial, strategic, investment, venture capital - Read more

THE UGLY
Politics & Policy

Flagship Pioneering CEO warns U.S. risks destroying biotech innovation amid government cuts and science skepticism
Innovation ecosystem, drug development, healthcare ecosystem - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here